SAB Biotherapeutics (SABS) Short Interest Ratio & Short Volume → Trump’s arrest is phase one (From Porter & Company) (Ad) Free SABS Stock Alerts $2.64 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SAB Biotherapeutics Short Interest DataCurrent Short Interest22,500 sharesPrevious Short Interest22,500 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$88,425.00Short Interest Ratio1.2 Days to CoverLast Record DateMay 15, 2024Outstanding Shares9,230,000 sharesFloat Size7,490,000 sharesShort Percent of Float0.30%Today's Trading Volume4,222 sharesAverage Trading Volume17,406 sharesToday's Volume Vs. Average24% Short Selling SAB Biotherapeutics ? Sign up to receive the latest short interest report for SAB Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSABS Short Interest Over TimeSABS Days to Cover Over TimeSABS Percentage of Float Shorted Over Time Ad Paradigm PressElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. SAB Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202422,500 shares $88,425.00 No Change0.3%1.2 $3.93 4/30/202422,500 shares $96,525.00 -12.1%0.3%1.7 $4.29 4/15/202425,600 shares $111,616.00 -11.4%0.3%1.8 $4.36 3/31/202428,900 shares $131,206.00 +38.3%0.4%1.7 $4.54 3/15/202420,900 shares $115,368.00 -15.0%0.3%1.1 $5.52 2/29/202424,600 shares $109,716.00 -37.1%0.3%1.5 $4.46 Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202439,100 shares $217,005.00 +17.8%0.5%2.9 $5.55 1/31/202433,200 shares $199,200.00 +90.8%0.4%2.8 $6.00 1/15/202417,400 shares $104,052.00 -2.8%0.2%1.5 $5.98 12/31/202317,900 shares $12,306.25 -91.4%N/A2.1 $0.69 12/15/2023207,600 shares $153,291.84 -11.2%0.3%3 $0.74 11/30/2023233,700 shares $227,156.40 +1.7%0.7%3.8 $0.97 11/15/2023229,800 shares $209,118.00 -12.1%0.6%4.4 $0.91 10/31/2023261,400 shares $261,373.86 -2.2%0.7%5.2 $1.00 10/15/2023267,200 shares $187,574.40 -2.8%0.7%6.4 $0.70 9/30/2023274,900 shares $173,187.00 -10.3%0.7%7.4 $0.63 9/15/2023306,500 shares $199,225.00 -17.5%0.8%8.5 $0.65 8/31/2023371,600 shares $267,552.00 +8.8%1.0%7 $0.72 8/15/2023341,500 shares $269,785.00 -12.3%0.9%5.9 $0.79 7/31/2023389,300 shares $315,333.00 -12.4%1.1%4.7 $0.81 7/15/2023444,400 shares $385,472.56 -4.1%1.3%1.6 $0.87 6/30/2023463,200 shares $384,456.00 +27.2%1.3%0.3 $0.83 6/15/2023364,300 shares $329,691.50 -14.9%1.0%0.3 $0.91 5/31/2023428,100 shares $381,009.00 -35.7%1.2%0.3 $0.89 5/15/2023665,400 shares $585,552.00 +28.3%1.9%0.5 $0.88 4/30/2023518,600 shares $465,858.38 +287.6%1.5%0.4 $0.90 4/15/2023133,800 shares $97,071.90 -3.2%0.4%0.1 $0.73 3/31/2023138,200 shares $60,808.00 -30.1%0.4%3.4 $0.44 3/15/2023197,800 shares $100,878.00 +17.5%0.6%4.3 $0.51 2/28/2023168,300 shares $109,395.00 +14.1%0.5%3.2 $0.65 2/15/2023147,500 shares $97,792.50 -2.8%0.5%2.7 $0.66 1/31/2023151,700 shares $103,064.98 +3.1%0.5%2.3 $0.68 1/15/2023147,100 shares $109,427.69 -14.4%0.5%2.1 $0.74 12/30/2022171,800 shares $101,344.82 -14.4%0.6%2.5 $0.59 12/15/2022200,700 shares $184,684.14 -6.1%0.7%2.8 $0.92 11/30/2022213,700 shares $230,796.00 -11.1%0.8%2.8 $1.08 11/15/2022240,300 shares $254,718.00 +8.2%0.9%3.1 $1.06 10/31/2022222,200 shares $199,980.00 -15.3%0.8%3.1 $0.90 10/15/2022262,400 shares $208,634.24 +7.7%0.9%3.8 $0.80 9/30/2022243,600 shares $170,763.60 +22.8%0.9%3.6 $0.70Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… 9/15/2022198,300 shares $164,589.00 -22.1%0.7%3.6 $0.83 8/31/2022254,600 shares $178,245.46 +6.3%1.0%4.5 $0.70 8/15/2022239,500 shares $287,400.00 -6.4%0.9%4.9 $1.20 7/31/2022255,900 shares $276,372.00 -3.4%1.0%5.3 $1.08 7/15/2022265,000 shares $315,350.00 -8.8%1.0%5.7 $1.19 6/30/2022290,700 shares $421,515.00 +17.1%1.1%4.5 $1.45 6/15/2022248,300 shares $330,239.00 -19.8%1.0%1.2 $1.33 5/31/2022309,600 shares $606,816.00 +19.8%1.2%1.5 $1.96 5/15/2022258,500 shares $514,415.00 -2.5%1.1%1.1 $1.99 4/30/2022265,100 shares $662,750.00 +3.7%1.1%1.2 $2.50 4/15/2022255,700 shares $736,416.00 -12.8%1.0%1.1 $2.88 3/31/2022293,200 shares $1.10 million -6.7%1.2%1.3 $3.76 3/15/2022314,400 shares $572,208.00 -30.0%1.3%2.9 $1.82 2/28/2022449,000 shares $2.23 million -5.9%1.8%2.7 $4.96 2/15/2022477,000 shares $2.57 million -0.1%1.9%2.3 $5.39 1/31/2022477,400 shares $2.77 million +19.7%1.9%1.9 $5.81 1/15/2022398,700 shares $2.69 million -26.9%1.6%1 $6.75 12/31/2021545,400 shares $4.26 million No Change2.2%0.8 $7.81 SABS Short Interest - Frequently Asked Questions What is SAB Biotherapeutics' current short interest? Short interest is the volume of SAB Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 22,500 shares of SABS short. 0.30% of SAB Biotherapeutics' shares are currently sold short. Learn More on SAB Biotherapeutics' current short interest. What is a good short interest ratio for SAB Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SABS shares currently have a short interest ratio of 1.0. Learn More on SAB Biotherapeutics's short interest ratio. What is a good short interest percentage for SAB Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.30% of SAB Biotherapeutics' floating shares are currently sold short. What is SAB Biotherapeutics' float size? SAB Biotherapeutics currently has issued a total of 9,230,000 shares. Some of SAB Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. SAB Biotherapeutics currently has a public float of 7,490,000 shares. How does SAB Biotherapeutics' short interest compare to its competitors? 0.30% of SAB Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to SAB Biotherapeutics: Curis, Inc. (1.11%), Fortress Biotech, Inc. (11.49%), Bolt Biotherapeutics, Inc. (8.82%), Molecular Templates, Inc. (3.66%), Amgen Inc. (1.92%), Vertex Pharmaceuticals Incorporated (1.46%), Regeneron Pharmaceuticals, Inc. (1.48%), Gilead Sciences, Inc. (1.75%), Biogen Inc. (2.41%), Alnylam Pharmaceuticals, Inc. (2.01%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short SAB Biotherapeutics stock? Short selling SABS is an investing strategy that aims to generate trading profit from SAB Biotherapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against SAB Biotherapeutics? A short squeeze for SAB Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SABS, which in turn drives the price of the stock up even further. How often is SAB Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SABS, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Curis Short Interest Data Fortress Biotech Short Interest Data Bolt Biotherapeutics Short Interest Data Molecular Templates Short Interest Data Amgen Short Interest Data Vertex Pharmaceuticals Short Interest Data Regeneron Pharmaceuticals Short Interest Data Gilead Sciences Short Interest Data Biogen Short Interest Data Alnylam Pharmaceuticals Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SABS) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.